All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Gam-COVID-Vac
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik V
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2021
Details:
These study indicate that Sputnik V triggers the production of antibodies and immune cells that target the SARS-CoV-2 coronavirus and may help protect against COVID-19.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Gam-COVID-Vac
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik V
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 21, 2021
Details:
The Russian Direct Investment Fund announces the UAE Ministry of Health and Prevention (MOHAP) has authorized the use of Russian Sputnik V vaccine in the fight against the coronavirus pandemic.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Gam-COVID-Vac
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik V
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2021
Details:
Abu Dhabi has started Phase III clinical trials of Russia’s Sputnik V COVID-19 vaccine amid a surge in infections in the United Arab Emirates. Two doses of the vaccine will be given, 20 days apart, to volunteers.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Gam-COVID-Vac
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik V
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 30, 2020
Details:
The Sputnik vaccine is being developed by Moscow's Gamaleya Research Institute and marketed by the Russian Direct Investment Fund (RDIF). Brazilian partner Uniao Quimica, a pharmaceutical company, entered the request with Anvisa.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Gam-COVID-Vac
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik V
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: The Gamaleya National Center of Epidemiology and Microbiology
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 23, 2020
Details:
Registering the Sputnik V vaccine based on the data from clinical trials in Russia confirms ANMAT’s high confidence in Russian regulatory standards.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Gam-COVID-Vac
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik V
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: The Gamaleya National Center of Epidemiology and Microbiology
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2020
Details:
The Russian Direct Investment Fund (RDIF) has confirmed efficacy of over 90% for the Sputnik V vaccine. The Sputnik V vaccine efficacy against severe cases of coronavirus was 100%.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
